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PD1-based DNA vaccine amplifies HIV-1 
GAG-specific CD8+ T cells in mice
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Yuanxi Kang,1 Xiaofan Lu,1 Li Liu,1 Kwok-Yung Yuen,1,2 and Zhiwei Chen1,2
1AIDS Institute and Department of Microbiology and 2Research Center for Infection and Immunity, Li Ka Shing Faculty of Medicine,  
The University of Hong Kong, Hong Kong, China.
Viral vector–based vaccines that induce protective CD8+ T cell immunity can prevent or control patho-
genic SIV infections, but issues of preexisting immunity and safety have impeded their implementation 
in HIV-1. Here, we report the development of what we believe to be a novel antigen-targeting DNA vaccine 
strategy that exploits the binding of programmed death-1 (PD1) to its ligands expressed on dendritic cells 
(DCs) by fusing soluble PD1 with HIV-1 GAG p24 antigen. As compared with non–DC-targeting vaccines, 
intramuscular immunization via electroporation (EP) of the fusion DNA in mice elicited consistently high 
frequencies of GAG-specific, broadly reactive, polyfunctional, long-lived, and cytotoxic CD8+ T cells and 
robust anti-GAG antibody titers. Vaccination conferred remarkable protection against mucosal challenge 
with vaccinia GAG viruses. Soluble PD1–based vaccination potentiated CD8+ T cell responses by enhancing 
antigen binding and uptake in DCs and activation in the draining lymph node. It also increased IL-12–pro-
ducing DCs and engaged antigen cross-presentation when compared with anti-DEC205 antibody-mediated 
DC targeting. The high frequency of durable and protective GAG-specific CD8+ T cell immunity induced by 
soluble PD1–based vaccination suggests that PD1-based DNA vaccines could potentially be used against 
HIV-1 and other pathogens.
Introduction
HIV-1 is one of the most devastating infectious agents existing 
worldwide for the past 30 years. Viral latency, high rates of muta-
tion during viral replication, and emergence of drug-resistant 
strains are posing problems for highly active antiretroviral ther-
apy (HAART) despite the ongoing development of newer drugs 
(1–3). An effective vaccine against HIV-1, therefore, remains a 
top priority in the fight against this pandemic virus. The induc-
tion of a high frequency of protective T cell immunity is a pre-
requisite for the successful control by a vaccine of intracellular 
pathogenic infections, and this has been well documented in 
the case of HIV-1 (4–7). Viral vector–based vaccines that induce 
such immunity can prevent or control pathogenic SIV infec-
tions, but issues of preexisting immunity and safety surround 
their implementation (8–10). DNA vaccines have shown a certain 
effectiveness, with a low level of toxicity in animal and human 
trials (11). However, conventional DNA vaccines with only the 
encoded antigen failed to mount a high frequency of effective 
CD8+ T cell immunity, even when delivered by in vivo electropo-
ration (EP) (12, 13). Therefore, targeting DNA vaccines to cells 
with ample antigen-presenting capacity, such as dendritic cells 
(DCs), has been the focus in recent years. Significant progress has 
been made, including DNA vaccines delivered by EP, in targeting 
antigens to DCs via various surface proteins expressed by DCs in 
order to augment antibody and T cell responses. However, target-
ing via anti-DEC205 antibody and soluble (s)CTLA-4 (cytotoxic 
T lymphocyte antigen 4) resulted in only a low frequency of anti-
gen-specific CD8+ T cell immunity (14–18). To date, it remains 
unclear which DC receptor targets would intensify antigen- 
specific CD8+ T cell immunity.
Along these lines, targeting vaccine antigens to DCs via the native 
ligands of programmed death-1 (PD1/CD279), namely PD-L1/
CD274 and PD-L2/CD273, in order to enhance immunogenicity has 
not been studied before. PD-L1 is constitutively expressed on T cells, 
B cells, macrophages, and DCs, whereas PD-L2 is found on DCs and 
activated monocytes and macrophages (19, 20). The essential role of 
the PD1/PD-L pathway in modulating immunity against chronic 
viral infections (e.g., HIV, HCV) and cancer has been well estab-
lished (21–24). Upregulated expression of PD1 is associated with the 
exhaustion of T and B cell functions. Thus, blockade of the PD1/
PD-L pathway using anti-PD1 antibody or a soluble form of PD1 
(sPD1) that contains only the extracellular domain rescues exhaust-
ed T cell responses and enhances antiviral and antitumor immunity 
(25–27). The role of sPD1 in modulating adaptive immune responses 
in the context of vaccination remains largely unknown. Since the 
level and distribution of PD-L expression on DCs may be different 
from other DC receptors (e.g., DEC205), it is of interest to determine 
whether an sPD1-based vaccine would elicit adaptive immunity with 
unique characteristics. We therefore hypothesize that an sPD1-based 
vaccine may improve adaptive T cell immunity by targeting vaccine 
antigens to DCs via PD-L1/L2 in vivo. To test this hypothesis, we 
chose HIV-1 GAG p24 as a test antigen because it has been com-
monly used in other DC-targeting strategies as a model immunogen 
(15, 28). Moreover, mounting evidence supports an essential role of 
potent and durable GAG-specific CD8+ T cell immunity in contain-
ing SIV/HIV infections (9, 29, 30), but conventional HIV-1 vaccina-
tion has been disappointing in terms of inducing these responses 
preclinically and clinically (11, 31–34). In this study, we report what 
we believe to be a novel sPD1-based DNA/EP vaccination strategy 
that is uniquely immunogenic in its ability to induce high frequen-
cies of durable, polyfunctional, cytotoxic, and protective GAG-spe-
cific CD8+ T cells. Moreover, we uncovered possible mechanisms 
underlying the greatly enhanced immunogenicity of this strategy.
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Results
Generation of sPD1-based fusion DNA vaccines. Three DNA vaccines: 
p24fc, sPD1-p24fc, and sΔPD1-p24fc, consisting of various combi-
nations of sPD1 or sΔPD1, HIV-1 GAG p24 (p24), and rabbit Fc 
(fc) were designed and generated to test our working hypothesis 
(Figure 1A). The rabbit Fc helps protein detection and purification 
but does not contain its receptor-binding domain (FcR). sΔPD1 
does not bind PD1 ligands due to 2 amino acid deletions in the 
IgV region (35, 36). The expression of fusion proteins encoded by 
these DNA vaccines was detected by Western blot analysis using 
either anti-GAG p24 (Figure 1B, top) or anti-rabbit Fc antibody 
(Figure 1B, bottom). To determine whether recombinant pro-
teins expressed from these DNA vaccines could interact with PD1 
ligands, we purified corresponding soluble proteins for binding 
to 293T cells transiently expressing PD-L1 or PD-L2 and used a 
detection antibody against rabbit Fc for analysis with flow cytom-
etry (Figure 1C). Indeed, PD-L1 and PD-L2 interacted only with 
recombinant sPD1-p24fc protein, but not with sΔPD1-p24fc or 
p24fc proteins.
sPD1-p24fc/EP DNA vaccination enhances p24-specific CD8+ T cell 
immunity and antibody responses in vivo. The 3 DNA vaccines were 
subsequently evaluated in vivo for their immunogenicity. Since 
intramuscular EP (referred to hereafter as i.m./EP) improves the 
immunogenicity of DNA vaccines by enhancing antigen expression 
and recruiting DCs as previously described (16, 37, 38), we per-
formed sPD1-p24fc/EP vaccination in BALB/c mice with an initial 
dose of 20 μg DNA per shot. We monitored the degree of immune 
responses 2 weeks after each of the 3 vaccinations (Figure 2A) (31). 
Compared with non–DC-targeting p24fc/EP and sΔPD1-p24fc/EP, 
we found that 3 vaccinations with sPD1-p24fc/EP were essential 
for eliciting stronger p24-specific T cell responses, with increases 
in splenocytes (greater than 2-fold) against the H2-Kd–restricted 
CD8 epitope GAG A-I (approximately 900 spot-forming units 
[SFUs] per 106 cells; Figure 2B) as well as IgG1 (Th2; ~8-fold) and 
IgG2a (Th1; ~4-fold) antibody responses (Figure 2C) detected by 
IFN-γ+ ELISPOT and ELISA, respectively. In particular, p24-specific 
CD8+ T cell responses were consistently more than 10-fold higher 
than those of CD4+ T cells among all animals tested (Figure 2B). 
We therefore proceeded with this standard immunization schedule 
throughout our studies. Critically, since the persistence of induced 
memory immunity over a long period is important to assess the 
efficacy of a vaccine, we also determined whether the enhanced 
p24-specific CD8+ T cell immunity and antibody responses were 
long lived. Groups of mice were studied 7.5 months after the third 
immunization. Compared with what was observed 2 weeks after 
the last vaccination (Figure 2, B and C), only the sPD1-p24fc/EP vac-
cination maintained long-lived p24-specific memory CD8+ T cells 
(~2-fold decrease; Figure 2D), minimal p24-specific memory CD4+ 
T cells (less than a 5-fold decrease; Figure 2E), and enhanced IgG1 
and IgG2a antibody responses (~2-fold increase; Figure 2F).
Dose-dependent enhancement of broadly reactive p24-specific CD8+ 
T cell immunity and antibody responses by sPD1-p24fc/EP vaccination. 
To determine the dose effect of sPD1-p24fc/EP vaccination, we 
performed immunization using a 100-μg dose of DNA following 
the same immunization schedule (Figure 2A) (31). Indeed, com-
pared with the 20-μg dose, we found a further 2-fold increase in 
both CD8+ and CD4+ T cell responses (Figure 3, A and B), as well 
as a greater than 10-fold increase in IgG1 and IgG2a antibody 
Figure 1
Expression and binding characteristics of DNA vaccine constructs. (A) Schematic representation of constructs encompassing the soluble form of 
PD1 (sPD1) or with 2 amino acid deletions essential for binding with PD-L1/L2 (sΔPD1), p24, and rabbit Fc under the CMV promoter, denoted as 
sPD1-p24fc, sΔPD1-p24fc, and p24fc, respectively. All constructs contain a tissue plasminogen activator (tPA) signal sequence. Rabbit Fc was used 
as a tag for purification and detection purposes. (B) Expression of fusion constructs as purified recombinant proteins examined by Western blot. 
Upper and lower blots show proteins detected by anti-HIV GAG or anti-rabbit Fc antibody, respectively. Smaller-sized bands (lower panel arrows) 
represent p24fc, while the larger-sized bands (upper panel arrows) represent sPD1-p24fc or sΔPD1-p24fc. Lanes are identified by the legend and 
numbers in kDa indicate marker sizes. (C) 293T cells were transiently transfected with PD-L1 or PD-L2 expression vectors, and the binding 
profiles of recombinant proteins were examined by flow cytometry using anti-rabbit Fc-FITC detection antibody (gray line). Controls included 
transfected 293T cells stained with anti-rabbit Fc-FITC antibody (negative, shaded line) or anti-mouse PD-L1 or L2 antibodies (positive, solid line).
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responses in immunized BALB/c mice 2 weeks after the last vac-
cination (Figure 3C, left), suggesting a dose-dependent effect. 
Since T cell immune response is important in the elimination of 
HIV-1–infected cells, we further tested the epitope specificity of 
p24-specific T cells. In this case, 3 nonoverlapping peptide pools 
spanning the entire p24 protein were used as stimuli, and 800–
1,000 ELISPOTs per 106 splenocytes were detected with each of 
these pools (Figure 3D, left), indicating substantial breadth of the 
elicited T cell response in recognizing p24 antigen. Furthermore, 
we were able to reproduce these results in C57BL/6 mice, show-
ing consistently greater T cell and antibody responses induced by 
sPD1-p24fc/EP vaccination. The significantly enhanced antibody 
response was skewed toward a Th2 response in C57BL/6 mice, as 
indicated by a relatively higher IgG1 reactivity than Th1-related 
IgG2c antibody reactivity (Figure 3C, right; P < 0.05). Moreover, 
close to 1,000 ELISPOTs per 106 splenocytes were detected with 
p24 pool 3, while the variable levels of responses to p24 pools 1 
and 2 were probably due to the genetic differences between BAL-
B/c and C57BL/6 mice (e.g., H2-Kd versus H2-Kb) (Figure 3D). Of 
critical note, more than 13% and 22% of CD8+ T cells in the spleen 
were positive for H2-Kd-GAG A-I tetramer binding in the 20-μg 
and 100-μg sPD1-p24fc dose groups of BALB/c mice, respectively, 
which were substantially higher percentages than those in the 
sΔPD1-p24fc or p24fc groups (Figure 4, A and B) (39). In addition, 
we evaluated the long-term memory CD8+ T cell responses iso-
lated from BALB/c mice 7.5  months after their final 100-μg dose 
of DNA vaccine. Statistically significant CD8+ T cell ELISPOT 
responses were detected only in sPD1-p24fc/EP–immunized mice 
(Figure 4C; P < 0.01). Importantly, a CFSE proliferation assay of 
CD8+ T cell response to p24 antigen was also performed to con-
firm the long-term memory responses. Memory CD8+ T cell pro-
liferation was detected only in sPD1-p24fc mice (Figure 4D). Taken 
together, sPD1-p24fc/EP DNA vaccination elicited, in a dose-
dependent manner, robust CD8+ T cell immunity with extended 
epitopic breadth of p24 specificity, enhanced anti-p24 antibody, 
and long-term memory responses.
Amplification of polyfunctional and cytotoxic p24-specific CD8+ T cell 
immunity by sPD1-p24fc/EP vaccination. Given the importance of 
polyfunctional CD8+ T cell response in controlling SIV/HIV-1 
infection (9, 40), we measured the ability of p24-specific T cell 
Figure 2
Induction of enhanced and long-lasting p24-specific immune responses by sPD1-p24fc vaccination in optimized conditions. (A) DNA vaccine immuni-
zation schedule for BALB/c mice. Mice were immunized at weeks 0, 3, and 6. For assessing overall immune response, mice were sacrificed 2 weeks 
after the last immunization to collect spleen and blood for analysis of cellular and humoral immune responses. (B) BALB/c mice were immunized 
with sPD1-p24fc, sΔPD1-p24fc, and p24fc at a dose of 20 μg DNA delivered via i.m./EP. Mice that received PBS only served as negative controls. Two 
weeks after each vaccination, ELISPOT assays for CD8+ T cells and CD4+ T cells were performed to test the ability of T cells to produce IFN-γ in 
specific response to HIV-1 GAG p24 epitopes GAG A-I (CD8) and GAG 26 (CD4), respectively, as well as to (C) IgG1 and IgG2a antibodies specific 
to HIV-1 p24 in sera detected by ELISA. To determine long-lived immunity, mice were rested for 7.5 months following the immunization regimen before 
being sacrificed. ELISPOT assays were performed for (D) CD8+ T cells and (E) CD4+ T cells to test their ability to produce IFN-γ in specific response 
to HIV-1 GAG p24 epitopes GAG A-I and GAG 26, respectively. (F) Specific IgG1 and IgG2a antibodies against HIV-1 GAG p24 detected by ELISA. 
Data show the means with standard error from 3 independent immunization experiments with 3 mice per group. *P < 0.05; **P < 0.01.
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populations from immunized mice to secrete IFN-γ, TNF-α, and 
IL-2 in response to p24 peptide pool stimulation. Our gating strat-
egy of intracellular cytokine flow cytometric analysis is depicted 
in Figure 5A; this strategy allowed us to separate CD8+ T or CD4+ 
T cells into subsets based on their ability to produce one or more 
cytokines (IFN-γ, TNF-α, and IL-2). Compared with sΔPD1-p24fc/
EP, the sPD1-p24fc/EP vaccination elicited substantially higher 
frequencies of p24-specific IFN-γ+CD8+ T cells, with up to 47.1% 
of total splenic CD8+ T cells (Figure 5A) producing either IFN-γ 
alone (21.0%), dual IFN-γ/TNF-α (22.3%), or triple IFN-γ/TNF-α/
IL-2 (4.7%) (Figure 5B). The frequencies of p24-specific CD4+ T 
cells producing IFN-γ alone (2.9%), IFN-γ/TNF-α (3.7%), or IFN-γ/
TNF-α/IL-2 (0.9%) were elevated as well with the sPD1-p24fc/EP 
vaccination (Figure 5C). Interestingly, the proportional order of 
effector CD8+ and CD4+ T cell subpopulations in response to p24 
stimulation was similar, with IFN-γ+/TNF-α+ being greater than 
IFN-γ+, which in turn was greater than IFN-γ+/TNF-α+/IL-2+. The 
high frequencies of effector cells secreting IFN-γ/TNF-α (CD8+: 
44.8%; CD4+: 39.5%), IFN-γ (CD8+: 42.2%; CD4+: 30.4%), and IFN-γ/
TNF-α/IL-2 (CD8+: 9.4%; CD4+: 9.7%) among the total p24-specific 
CD8+ and CD4+ T cell populations are indicative of enhanced vac-
cine potency induced by sPD1-p24fc/EP vaccination (Figure 5D).
Since cytotoxic T cell quality is essential for the elimination 
of infected cells, we used the mouse mesothelioma cell line AB1 
transduced to express HIV-1 GAG (41). Forty-three percent of the 
AB1-HIV-1-GAG cells readily expressed HIV-1 p24 (Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; doi:10.1172/JCI64704DS1), and these cells were used as target 
cells for the cytotoxicity assay. Since total splenocytes isolated from 
sPD1-p24fc/EP–immunized mice showed stronger target cell killing 
effects (Supplemental Figure 1B), we further examined the effec-
tiveness of purified CD8+ and CD4+ T cells from splenocytes using 
the same assay. As shown in Figure 5E, a high percentage of dead 
target cells was detected after coculture with CD8+ T cells from 
sPD1-p24fc/EP–immunized mice, even at an effector/target cell 
ratio (E/T) of 0.1:1, compared with the p24fc/EP control group. To 
our surprise, purified CD4+ T cells after sPD1-p24fc/EP vaccination 
also showed cytotoxic function starting from a 1:1 ratio (Figure 
5F), suggesting an extended effect of the sPD1-p24fc/EP vaccina-
tion that could be overshadowed by the induction of a robust level 
of p24-specific polyfunctional and cytotoxic CD8+ T cell immunity.
Efficacy of p24-specific T cell immunity. To investigate whether cellu-
lar immunity elicited by sPD1-p24fc/EP leads to protection, groups 
of BALB/c mice were first challenged intranasally with 4 × 107 PFUs 
of VTTgagpol (a modified vaccinia virus Tian Tan strain that expresses 
HIV-1 gagpol) 3 weeks after the last vaccination with sPD1-p24fc/
EP or controls at a dose of 20 μg. Three days later, viral titers in 
the lungs were quantified using a plaque-forming assay as we pre-
viously described (42). Compared with p24fc/EP and sΔPD1-p24fc/
EP groups, there were dramatically reduced viral titers detected in 
Figure 3
Comparison of sPD1-p24fc elicited antigen-
specific immunity in 2 mice models. BALB/c 
and C57BL/6 mice were vaccinated with 
sPD1-p24fc, sΔPD1-p24fc, and p24fc at a 
dose of 100 μg DNA i.m/EP according to 
the immunization schedule. (A) IFN-γ–
producing CD8+ and (B) CD4+ cells were 
measured by ELISPOT assay in BALB/c 
splenocytes stimulated using the specific 
peptides GAG A-I and GAG 26, respec-
tively. (C) Specific antibodies against HIV-1 
GAG p24 detected by ELISA. IgG1 (Th2) 
was tested in both strains of mice, while 
IgG2a was detected in BALB/c mice and 
IgG2c was detected in C57BL/6 mice. (D) 
IFN-γ–secreting cells from splenocytes 
isolated from BALB/c or C57BL/6 mice 
in response to stimulation using 3 differ-
ent nonoverlapping peptide pools derived 
from 59 peptides spanning the entire HIV-1 
GAG p24 region as detected by ELISPOT. 
Data show the means with standard error 
from 3 independent immunization exper-
iments with 3 mice per group. *P < 0.05; 
***P < 0.001.
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mice vaccinated with sPD1-p24fc/EP (P < 0.005 and P < 0.01, respec-
tively) (Figure 6A). VTTgagpol, however, is considered an attenuated 
nonvirulent virus in mice, and the protective effect may be different 
with pathogenic infection. For this reason, we subsequently gener-
ated a virulent vaccinia Western Reserve strain expressing HIV-1 
gagpol (WRgagpol) to challenge mice immunized with a 100-μg DNA 
vaccine. With an intranasal dose of 2 × 106 PFUs of WRgagpol, mice 
immunized with the placebo, sΔPD1-p24fc/EP, or p24fc/EP showed 
greater than 25% body weight loss within 8 days. This contrasts 
with the mice immunized with sPD1-p24fc/EP that showed less 
than 7% body weight loss (Figure 6B), with a corresponding sig-
nificant reduction in virus titers in the lungs of this group of mice 
compared with controls (Figure 6C; P < 0.01). Since there was no 
antivaccinia immunity involved, our data indicate that p24-specific 
T cell immunity induced by sPD1-p24fc/EP provided substantial 
protection against mucosal challenge in 2 mouse model systems.
Factors contributing to the enhanced immunogenicity of sPD1-p24fc/
EP vaccination. To investigate the underlying mechanism of sPD1-
p24fc/EP vaccination, we compared 4 groups of animals for DNA 
vaccination: (a) with EP; (b) no EP; (c) EP/no fusion (i.e., individual 
sPD1fc and/or p24fc DNA constructs administered simultaneously 
with EP at the same or different injection sites); and (d) EP/no Fc 
(sPD1-p24 without the rabbit Fc tag). The latter 3 groups were 
included to determine the role of EP, protein fusion, and rabbit Fc, 
respectively, in the induction of enhanced antigen-specific T and B 
cell immunity. Since CD8+ T cell immune response was low in the 
“no-EP” animals (data not shown), we used a high dose (100 μg) of 
sPD1-p24fc DNA for this comparison, whereas a suboptimal 20-μg 
dose was used for the other 3 groups. Several findings were made 
in comparison with group 1, which received the sPD1-p24fc/EP 
vaccination. First, the no-EP group elicited 7-fold less IFN-γ+CD8+ 
T cell ELISPOTs (Supplemental Figure 2A) and 13-fold less IgG2a 
(Th1) responses, despite a 5-fold increase in vaccine dose (Sup-
plemental Figure 2D), whereas comparable levels of IFN-γ+CD4+ 
T cell ELISPOTs and IgG1 (Th2) antibody responses were found 
(Supplemental Figure 2, B and C). Second, the EP/no-fusion group 
elicited noticeably less T cell (IFN-γ+CD8+ or IFN-γ+CD4+) and 
IgG2a antibody responses than group 1, with comparable levels 
Figure 4
Increased dose of DNA vaccine further enhanced p24-specific tetramer-positive and long-term memory CD8+ T cell responses. sPD1-p24fc, 
sΔPD1-p24fc, and p24fc were administered to BALB/c mice at a dose of 100 μg DNA delivered by i.m./EP. (A) HIV-1 p24-specific H2-Kd-AMQMLKD-
TI-PE tetramer staining of CD8+ T cell populations 2 weeks after the final immunization is shown in flow cytometric plots of 1 representative exper-
iment, or (B) in data represented as a column graph of immunization with 2 doses of 20 μg and 100 μg DNA. PBS represents the negative control. 
(C) Thirty weeks after the final i.m./EP vaccination at a dose of 100 μg DNA, IFN-γ–producing CD8+ T cells were measured by ELISPOT assay in 
splenocytes stimulated using specific GAG A-I epitope. (D) Splenocytes labeled with CFSE and stimulated with purified CD11c+ BM-DCs plus p24 
peptide pools and anti-CD28 for 5 days. Addition of anti-CD3 antibody served as a positive control. CFSE signals on CD8+ T cell populations were 
detected by flow cytometry. Data show the SEM from 3 independent immunization experiments with 3 mice per group. *P < 0.05; **P < 0.01.
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of IgG1 responses (Supplemental Figure 2). Thus, in our experi-
mental conditions, the adjuvant effect of sPD1fc was minimal, 
while the fusion protein was necessary for effective DC targeting. 
Finally, the EP/no-Fc group induced levels of T cell (IFN-γ+CD8+ 
or IFN-γ+CD4+) and antibody responses comparable to those in 
mice vaccinated with rabbit Fc-containing counterparts in group 
1 (Supplemental Figure 2), indicating that the Fc portion of the 
DNA fusion vaccine did not affect immunogenicity against HIV-1 
GAG p24. Overall, these findings indicate that the fusion DNA 
construct of sPD1-p24fc, combined with EP, is essential and is the 
best strategy for eliciting greatly enhanced CD8+ T cell and anti-
body responses. To further study the in vivo DC-targeting effect 
of sPD1-based DNA vaccination, we constructed sPD1-OVAfc 
and sΔPD1-OVAfc plasmids by replacing HIV-1 p24 antigen. We 
introduced CFSE-labeled OT-I cells into C57BL/6 mice 24 hours 
before vaccination via sPD1-OVAfc/EP, sΔPD1-OVAfc/EP, and 
sPD1-p24fc/EP, respectively. Five days later, OT-I cells in draining 
lymph nodes were analyzed by CFSE signals using flow cytometry. 
Figure 5
Polyfunctionality and cytotoxicity effects of sPD1-p24fc–induced T cells. BALB/c mice were immunized by i.m./EP with 3 injections of 100 μg 
sPD1-p24fc and sΔPD1-p24fc. Splenocytes were collected and analyzed by flow cytometry following intracellular staining using antibodies 
against IFN-γ, TNF-α, and IL-2. (A) Gating strategy for flow cytometric scatter plots to analyze the frequency of CD8+ or CD4+ T cells positive 
for IFN-γ, TNF-α, and/or IL-2. (B) Column graphs depicting subpopulations of single-, double-, or triple-positive CD8+ or (C) CD4+ T cells 
releasing the cytokines IFN-γ, TNF-α, and IL-2 induced by DNA vaccination of sPD1-p24fc and sΔPD1-p24fc (and PBS control). (D) Pie chart 
analysis representing subpopulations of total cytokine-secreting CD8+ or CD4+ T cells positive for combinations of IFN-γ, TNF-α, and IL-2. 
Columns and pie regions represent the mean values of 2 independent experiments with 3 mice per group, with error bars representing the 
SEM. (E) Purified CD8+ or (F) CD4+ T cells from sPD1-p24fc– and p24fc-immunized mice were stimulated by p24 peptide pools plus anti-CD28 
overnight before cytotoxicity assay with an AB1-HIV-1-GAG cell line as the target. Line graphs show the percentages of dead cells as a result 
of cell-mediated killing, with the baseline of natural target cell death percentage subtracted. *P < 0.05; **P < 0.01. 
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The results showed that, indeed, OVA-specific CD8+ T cells had 
greatly proliferated in mice injected with sPD1-OVAfc compared 
with sΔPD1-OVAfc and nonspecific sPD1-p24fc controls (Supple-
mental Figure 3), confirming enhanced in vivo DC targeting for 
antigen presentation.
sPD1-p24fc/EP is more effective than anti–DEC205-p24/EP at enhanc-
ing CD8+ T cell immunity. Anti-DEC205 antibody has been previ-
ously used to develop DC-targeting vaccines (15, 16). Here, we 
investigated the immunogenicity of 2 DC-targeting DNA vaccines, 
sPD1-p24fc and single-chain anti–DEC205-p41 (16), compared 
with non–DC-targeting controls, p24fc, p41 and PBS, in parallel 
experiments following the standard immunization schedule with 
a 100-μg dosage delivered via i.m./EP (Figure 2A). ELISPOT assay 
showed that sPD1-p24fc/EP and anti–DEC205-p41/EP elicited 
considerably higher levels of p24-specific CD8+ and CD4+ T cells 
than did p24fc/EP and p41/EP (Figure 7, A and B). Against the sin-
gle GAG A-I epitope, sPD1-p24fc/EP induced a significant 3-fold 
greater level of CD8+ T ELISPOTs than anti–DEC205-p41/EP 
(P < 0.05). Moreover, consistent with previous experiments, sPD1-
p24fc/EP induced close to 20% of the tetramer-positive CD8+ T cell 
populations, while anti–DEC205-p41/EP induced about half of 
that percentage, though this was higher than in the controls (Fig-
ure 7C). Analysis of the p24-specific antibody titers revealed that 
sPD1-p24fc/EP and anti–DEC205-p41/EP were similar for both 
IgG1 and IgG2a (Figure 7D). In addition,  we examined polyfunc-
tional CD8+ and CD4+ T cell subsets after p24 peptide pool stim-
ulation. As shown in Figure 7E, statistically significantly higher 
frequencies of CD8+ T cells were evident with sPD1-p24fc/EP than 
with anti–DEC205-p41/EP across 4 subpopulations, including 
IFN-γ+ alone (2.5-fold higher), IFN-γ+/TNF-α+ (4-fold higher), IFN-
γ+/IL-2+ (5-fold higher), and IFN-γ+/TNF-α+/IL-2+ (5-fold higher) 
(all P < 0.05). CD4+ T cells also displayed the same trend, but P 
values did not reach statistical significance (Figure 7F). These data 
demonstrate the overall superiority of sPD1-based DNA vaccine 
in enhancing antigen-specific CD8+ T cells compared with anti-
DEC205–mediated DC-targeting DNA vaccine.
sPD1-p24fc/EP vaccination uniquely enhances IL-12–producing DCs in 
vivo. To further investigate the underlying mechanism of sPD1-
p24fc/EP vaccination compared with anti–DEC205-p41/EP, we 
sought to determine the effects of the former on DCs in terms 
of antigen uptake, maturation and activation, and Th1 cytokine 
production — all of which may influence adaptive immunity (43, 
44). Although PD-L1 expressed in B cells and macrophages may 
lead to a broader cell range than DEC205 for exogenous antigen 
presentation, only DCs are capable of activating or cross-prim-
ing naive CD8+ T cells (45, 46). For proof-of-concept, we purified 
splenic CD11c+ DCs from mice and treated them with purified 
proteins sPD1-p24fc, p24fc, or anti–DEC205-p24 (28). We found 
that both anti–DEC205-p24 and sPD1-p24fc protein bound 
to splenic CD11c+ DCs in vitro at similar and much higher lev-
els than did p24fc protein (Supplemental Figure 4A), indicating 
proper binding with their respective receptors. Moreover, the 
detection of p24 antigen intracellularly after sPD1-p24fc (~6%) or 
anti–DEC205-p24 (~12%) binding (Supplemental Figure 4B) sug-
gests that antigen uptake had taken place. We then examined these 
findings in vivo. Groups of BALB/c mice were immunized with 
100 μg of sPD1-p24fc, anti–DEC205-p41 (16), or p24fc DNA via 
i.m./EP, and were sacrificed at 8, 16, and 24 hours to examine the 
level of p24 antigen uptake as well as the levels of costimulatory 
molecules and Th1 cytokines in CD11c+ DCs in draining lymph 
nodes. We consistently found that mice vaccinated with sPD1-
p24fc/EP and anti–DEC205-p41/EP displayed higher intracellular 
p24 signals compared with DCs from p24fc or PBS control mice 
at 8 hours (Supplemental Figure 5A). These results indicate that 
there was no significant difference between the 2 DC-targeting 
strategies in terms of antigen binding and uptake by DCs both 
in vitro and in vivo. Compared with the p24fc/EP control, how-
ever, only sPD1-p24fc/EP elicited statistically significantly higher 
expression of CD40 and MHC class II molecules on CD11c+ 
DCs at 16 hours in the draining lymph nodes (Figure 8, A and B; 
P < 0.05). We also found a relatively higher level of CD80 (Supple-
mental Figure 5B), but not CD86 (data not shown), expression on 
CD11c+ DCs at 24 hours despite the lack of statistical significance, 
suggesting direct effects on DC activation after sPD1-p24fc/EP. 
For comparison, no changes were found in PD-L1/L2 expression 
on DCs or PD1 expression on T cells in vivo (data not shown). Fur-
thermore, we examined the production of Th1 cytokines IL-12 and 
IFN-γ by CD11c+ DCs (47). Interestingly, the frequency of IL-12–
producing CD11c+ DCs was found to be significantly higher in 
the sPD1-p24fc/EP group than in the anti–DEC205-p41/EP or 
Figure 6
sPD1-based DNA vaccination–induced antigen-specific immunity confers protection against virulent viral challenge. (A) Mice previously immu-
nized with 20-μg DNA vaccines were challenged with 4 × 107 PFUs VTTgagpol three weeks after immunization to examine immune protection. 
Virus titers in the lungs of immunized mice were evaluated by examining plaque formation on Vero cell monolayers 3 days after challenge. Mice 
immunized with 100-μg DNA vaccines were challenged with 2 × 106 PFUs WRgagpol three weeks after immunization and weighed daily for 8 days. 
(B) Body weight percentage loss from day 0. (C) Mice were sacrificed on day 8 and virus titers in the lungs were evaluated by examining plaque 
formation on Vero cell monolayers. Data represent the SEM of 2 independent experiments with 5 mice per group. **P < 0.01; ***P < 0.001.
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p24fc/EP groups (Figure 8C; P < 0.05). On the other hand, the fre-
quency of IFN-γ–producing DCs was found to be similar between 
the sPD1-p24fc/EP and anti–DEC205-p41/EP groups (Figure 8D), 
but higher than that of the p24fc/EP group. Thus, these results 
suggest that although both DC-targeting strategies could acti-
vate DC production of IFN-γ, sPD1-p24fc/EP displayed a unique 
advantage in the activation of IL-12–producing DCs in vivo, which 
is important for the activation of CD8+ T cell immunity (45, 48).
sPD1-p24fc, but not anti–DEC205-p24, engages the antigen cross-presen-
tation pathway in DCs. Since sPD1-p24fc/EP or anti–DEC205-p41/
EP resulted in comparable p24 binding and uptake (Supplemental 
Figure 4 and Supplemental Figure 5A), but the former generated 
higher CD8+ T cell response in vivo, we speculated that the under-
lying antigen presentation pathway for CD4+ and CD8+ T cell acti-
vation is distinct (49). It has been documented that cross-presenta-
tion of exogenous antigen by DCs can drive the subsequent CD8+ 
T cell response independent of CD4+ T cell help (49, 50). After 
exogenous antigen uptake by DCs, the antigen is localized to early 
endosomes (Rab5+), then diverted to the Rab14+ compartment 
through MHC class I cross-presentation for CD8+ T cell activation 
(46) or late endosomal (Rab9+ or Lamp1+) routing to the lysosomal 
compartment that is apparently required for adequate processing 
and MHC class II presentation and subsequent CD4+ T cell activa-
tion (49, 51, 52). Thus, we performed colocalization experiments 
using p24 antigen and biomarkers of endosomal compartments in 
splenic CD11c+ DCs. We used sPD1-p24, anti–DEC205-p24, and 
p24 proteins (without the Fc tag) to treat DCs for 15 minutes, 30 
minutes, 1 hour, and 2 hours, respectively. Confocal microscopic 
analysis showed that both sPD1-p24 and anti–DEC205-p24 were 
colocalized with early Rab5+ endosomes, as well as with late Rab7+ 
Figure 7
DNA immunization of mice with sPD1-based vaccines elicits stronger antigen-specific CD8+ T cell responses compared with DEC205-based vac-
cines. BALB/c mice were administered 2 different DC-targeting DNA vaccines of sPD1-p24fc and psc-DEC205-p41 at a dose of 100 μg delivered 
via i.m./EP. p24fc, (psc-)Cont-p41, and PBS were used as controls. (A) IFN-γ–producing CD8+ and (B) CD4+ cells were measured by ELISPOT 
assay in splenocytes stimulated with the specific epitopes GAG A-I and GAG 26, respectively. (C) HIV-1 p24–specific H2-Kd-AMQMLKDTI-PE 
tetramer staining of CD8+ T cell populations is represented as a column graph of immunization. (D) Specific IgG1 and IgG2a antibodies against 
HIV-1 GAG p24 were detected in sera by ELISA. Intracellular staining performed on both CD4+ and CD8+ T cell populations in splenocytes is 
shown in column graphs depicting subpopulations of single-, double-, and triple-positive (E) CD8+ or (F) CD4+ T cells releasing the cytokines 
IFN-γ, TNF-α, and IL-2 induced by DNA vaccination. Data show the SEM with 5 mice per group. *P < 0.05.
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Figure 8
sPD1-based vaccine functions by activating DCs 
and engaging in cross-presentation. Mice were 
immunized with sPD1-p24fc, anti–DEC205-p41, 
and p24fc DNA vaccines, or PBS placebo, at a 
100-μg dose administered by i.m./EP. Column 
graphs show (A) surface expression of CD40 
and (B) MHC II, as well as intracellular staining 
of (C) IL-12 and (D) IFN-γ in draining lymph node 
CD11c+ DCs 16 hours after immunization. Data 
show the SEM with 5 mice per group. *P < 0.05. 
(E) Purified splenic CD11c+ DCs were treated with 
the proteins sPD1-p24, anti–DEC205-p24, or p24 
for 15 minutes and 1 hour. Formaldehyde-fixed 
DCs were immunostained for HIV-1 GAG, Rab 
14, and Lamp1. Nuclei were counterstained with 
DAPI. Images are overlays of the 3 signals (green: 
GAGp24; red: endosomal marker; blue: DAPI). 
(F) Schematic representation of the underlying 
mechanisms of sPD1-based vaccine. Following 
DC targeting of sPD1-p24fc (red arrows), antigen 
uptake into Rab5 endosomes was diverted to: (a) 
Rab14 endosomal compartment for subsequent 
MHC I cross-presentation; or (b) Rab7, Rab9, and 
Lamp1 endosomes, leading to MHC II presenta-
tion. Antigen presentation and activation of respec-
tive T cells are likely accompanied by increased 
costimulatory CD40 expression and production of 
Th1 cytokines IFN-γ and IL-12. By comparison, DC 
targeting of anti–DEC205-p24 (green arrows) was 
only routed to Lamp1 endosomes with induced 
IFN-γ production. Nontargeting p24 was only found 
in Rab7 endosomes (dotted blue arrow). The red 
cross symbol represents the HIV-1 antigen p24.
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and Rab9+ endosomes, and were subsequently found with Lamp1 
endosomes from 30 minutes to 1 hour onward when compared 
with the p24 controls (Figure 8D and Supplemental Figure 6). 
Importantly, by 15 minutes, sPD1-p24, but not anti–DEC205-p24, 
was found colocalized with Rab14 (Figure 8E and Supplemental 
Figure 6; the quantification of colocalization is shown in Supple-
mental Table 1). These data demonstrate that while both DC-tar-
geting strategies engage MHC class II (Lamp1) endosomes for the 
induction of CD4+ T cell responses, sPD1-p24 uniquely used the 
cross-presenting MHC class I (Rab14) endosomal compartments 
that likely underlie the enhanced CD8+ T cell response following 
vaccination (Figure 8F).
Discussion
In this study, we demonstrate that the sPD1-p24fc/EP DNA 
vaccination elicits remarkably enhanced cellular and humoral 
immune responses against HIV-1 GAG antigen. To the best of 
our knowledge, this is the first DNA vaccine strategy in BALB/c 
mice to use PD1 for the induction of strong HIV-1 GAG-specific 
CD8+ T cell immunity with broad reactivity, long-term memory, 
polyfunctionality, cytotoxicity, and protective function, which 
is unique compared with existing DNA vaccines. The markedly 
enhanced CD8+ T cell response is mainly due to more efficient 
antigen targeting to DCs, as well as to the subsequent activation 
and Th1 cytokine production of DCs in the draining lymph nodes 
of immunized mice compared with that achieved by non–DC-tar-
geting vaccines. In addition to these findings, sPD1-based vac-
cination displays unique advantages when compared with anti-
DEC205–based DC targeting in its capacity to induce a higher 
frequency of IL-12–producing DCs and to engage the antigen 
cross-presentation pathway in DCs for antigen-specific CD8+ 
T cell potentiation. Since DNA vaccination is safe and has no 
preexisting immunity issues (53), sPD1-based vaccine may offer a 
new and effective way to induce a high frequency of durable anti-
gen-specific CD8+ T cell immunity, which has implications for 
the prevention and treatment not only of HIV-1/AIDS but also of 
other infectious diseases and even cancer.
A high frequency of anti-GAG CD8+ T cell immunity is con-
sidered a critical characteristic of an effective T cell–based vac-
cine designed to suppress and contain SIV/HIV infections and 
facilitate the elimination of the latent viral reservoir after viral 
reactivation (9, 40, 54, 55). Here, sPD1-p24fc/EP DNA vaccina-
tion not only elicited high frequencies of IFN-γ+ spot–forming 
and tetramer-positive HIV-1–specific CD8+ T cells, but improved 
their polyfunctionality and cytotoxicity and conferred substan-
tial protection against mucosal challenge in mice with 2 types 
of vaccinia GAG viruses. As measured by ELISPOT assay for the 
specific CD8+ T cell epitope GAG A-I, sPD1-p24fc/EP elicited 
approximately 900 SFUs per 106 splenocytes at the 20-μg DNA 
dose, and a further rise to over 1,600 SFUs per 106 splenocytes at 
the 100-μg DNA dose (Figure 2B and Figure 3A). Compared with 
our previous DNA or viral vector–based vaccine candidates, 1 mg 
ADVAX (a codon-optimized HIV-1 DNA vaccine) administered 
i.m. only induced approximately 250 SFUs per 106 splenocytes 
(31), whereas the modified vaccinia Ankara–vectored (MVA-vec-
tored) HIV-1 vaccine ADMVA induced approximately 200 SFUs 
per 106 splenocytes against the GAG A-I epitope in BALB/c mice 
after 2 i.m. vaccinations at a dose of 106 TCID50 (32). Even for adju-
vant-assisted DNA vaccination in BALB/c mice against the same 
GAG A-I epitope, i.m. coadministration of IL-15 and HIV-1 GAG 
DNA elicited approximately 200–610 SFUs per 106 splenocytes at 
a dose of 50 to 100 μg DNA (56, 57). In addition, the 22% CD8+ 
GAG A-I tetramer–positive T cell response elicited with the 100-μg 
dose of sPD1-p24fc/EP (Figure 4) was comparable to that obtained 
with rAd5-GAG vaccines in BALB/c mice immunized 3 times at a 
high dose of 1010 virus particles, and to that observed in BALB/c 
mice immunized by a heterologous prime-boost protocol with 
2 live vectors (L. monocytogenes and Ad5) or by a DC-directed (via 
DC-SIGN) lentiviral system encoding HIV-1 GAG protein (39, 58). 
Furthermore, we show that up to 47.1% of total splenic CD8+ T 
cells were p24 specific and were releasing IFN-γ+ after GAG peptide 
pool stimulation (Figure 5A). And within the cytokine-producing 
CD8+ T cell population, the proportional distribution of polyfunc-
tional T subsets followed the order of IFN-γ+/TNF-α+ being greater 
than IFN-γ+, which in turn was greater than IFN-γ+/TNF-α+/IL-2+ 
(Figure 5D). These types of greatly enhanced polyfunctional anti-
GAG CD8+ T cell immunity were neither found with the 2 control 
vaccines in our parallel experiments, nor reported by the existing 
DNA vaccine strategies described above (56, 57, 59). Importantly, 
consistent with enhanced cytotoxic CD8+ and CD4+ T cell activ-
ity (Figure 5, E and F), challenge studies using 2 types of vaccinia 
GAG viruses have demonstrated the significantly improved vac-
cine efficacy offered by sPD1-p24fc/EP (Figure 6; P < 0.01). These 
findings suggest the potential for the development of an effective 
PD1-based DNA vaccine against HIV/AIDS in the future (9, 40).
Compared with non–DC-targeting vaccines, one of the key 
underlying mechanisms of sPD1-p24fc/EP vaccination depends 
on the functionality of sPD1 for more effective antigen targeting 
to DCs and subsequent enhanced DC activation in vivo. In this 
study, besides p24fc, we included sΔPD1-p24fc as a non–DC-tar-
geting control. sΔPD1-p24fc differs from sPD1-p24fc by 2 essential 
amino acids in the functional IgV domain of sPD1 (35, 36, 60), 
which renders the protein unable to interact with PD1 ligands 
expressed on either transfected cells (Figure 1C) or DCs (data not 
shown). Since there were substantial differences between sPD1-
p24fc/EP and sΔPD1-p24fc/EP in eliciting GAG-specific adaptive 
immunity (Figures 2–5), the intact sPD1 IgV domain is apparent-
ly essential to the functionality of the sPD1-based antigen in DC 
targeting. Our preliminary data showing a higher level of prolif-
erating OVA-specific OT-I cells after sPD1-OVAfc/EP vaccination 
provide further evidence for the role of sPD1-based DC targeting 
in CD8+ T cell potentiation in vivo (Supplemental Figure 3). Fur-
thermore, we demonstrate that the sPD1-p24fc fusion construct 
for DC targeting is critical because codelivery of sPD1fc and p24fc 
in trans by EP at the same or different anatomic sites did not 
achieve significantly enhanced CD8+ T cell response compared 
with sPD1-p24fc/EP (Supplemental Figure 2). This finding also 
suggests that the level of sPD1fc expression after EP vaccination 
likely does not achieve a strong adjuvant effect by blocking the 
PD1/PD-L signaling pathway to produce the same level of CD8+ 
T cell expression as sPD1-p24fc. In addition, unlike the non–DC-
targeting p24fc/EP control, sPD1-p24fc/EP resulted in consis-
tently higher levels of CD40, CD80, and MHC class II expression, 
as well as Th1 cytokine IL-12 and IFN-γ production in DCs, sug-
gesting an increased DC activation in draining lymph nodes that 
is critical for the potentiation of CD8+ T cell responses (Figure 8, 
A–D, Supplemental Figure 5B) (44, 45).
Various DC-targeting strategies that include DNA vaccines 
delivered by EP to strengthen HIV-1 GAG-specific immunity 
have been explored previously by others, but with limited suc-
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formed using polyethylenimine (PEI), and protein expression was detected 
by Western blot using both anti-rabbit Fc and anti-HIV GAG antibodies. 
Recombinant proteins were purified from the transfected cell supernatants 
by affinity chromatography using Protein G Sepharose (Invitrogen), and 
protein concentration was measured using a Micro BCA Protein Assay Kit 
(Thermo Scientific).
Binding characteristics of sPD1 fusion proteins. 293T cells (106 cells) tran-
siently expressing PD-L1 and PD-L2 were incubated with 2 μg of purified 
sPD1-p24fc, sΔPD1-p24fc, or p24fc fusion protein. Goat anti-rabbit IgG 
(HL)-FITC (Invitrogen) was used to capture the positive signals. Trans-
fected 293T cells stained by FITC-rat anti-mouse PD-L1 or PD-L2 antibod-
ies (eBioscience) and FITC-rat IgG1 isotype served as positive and negative 
controls, respectively. Data were acquired on a FACSCalibur instrument 
(BD Biosciences) and analyzed using CellQuest software (BD Biosciences).
Mouse immunization. All animal experiments were approved by the Com-
mittee on the Use of Live Animals in Teaching and Research at the Labo-
ratory Animal Unit of The University of Hong Kong. Five- to 8-week-old 
female BALB/c mice and C57BL/6 mice were bred under standard patho-
gen-free conditions in the Laboratory Animal Unit of The University of 
Hong Kong. Mice were housed in cages under standard conditions with 
regulated temperature and humidity, fed with pelted food and tap water, 
and cared for according to the criteria outlined in the Guide for the Care 
and Use of Laboratory Animals. OT-I and OT-II mice were provided by 
Kang Liu and were kept in the Rockefeller University laboratory (New York, 
New York, USA). The immunization procedure was similar to our previous 
protocols. Mice received 3 DNA immunizations by i.m. injection with or 
without EP given every 3 weeks at a dose of 20 μg or 100 μg per mouse. 
Two weeks after every immunization, blood samples were taken for sera 
antibody testing. Two weeks after the final immunization, the mice were 
sacrificed, and sera and splenocytes were collected for immune response 
analysis (Figure 2A).
ELISA. Specific antibody responses were assessed by ELISA as previ-
ously described (42). Briefly, high-affinity, protein-binding ELISA plates 
(BD Biosciences) were coated with HIV-1 p24 protein (Abcam). Serial-
diluted sera were then added and antibodies detected with HRP-labeled 
anti-mouse IgG1 or IgG2a (or IgG2c for C57BL/6 mice sera) antibody 
(Sigma-Aldrich). Relative antibody titers were expressed as the reciprocal 
highest dilution of samples producing at least a 2-fold greater optical den-
sity readout than that of the control serum sample at the same dilution.
Evaluation of HIV-1 Gag p24-specific T cell responses. IFN-γ–producing T cells 
were evaluated by an ELISPOT assay (Millipore) as previously described 
(32). Ten micrograms per milliliter of HIV-1 p24 peptide or peptide pools 
(at a final concentration of 2 μg/ml for each peptide, donated by the NIH, 
catalog no. 8117) were used to stimulate splenocytes in vitro. Peptide 
pools consisting of 59-member GAG p24 libraries (each peptide contained 
15aa with 10aa overlap) were divided into 3 pools of 19 to 20 peptides 
spanning amino acids 1–87 (pool 1), 77–167 (pool 2), and 157–231 (pool 
3). Peptide GAG A-I (AMQMLKDTI) is specific to CD8+ T cells, whereas 
peptide GAG 26 (TSNPPIPVGDIYKRWIILGL) is specific to CD4+ T cells. 
Cells stimulated with 500 ng/ml phorbol 12-mystrate 13-acetate (PMA; 
Sigma-Aldrich) plus 1 μg/ml calcium ionocycin or left in media only 
served as positive and negative controls, respectively. Cells were incubated 
at 37°C, 5% CO2, and 100% humidity for 20 hours. Spots were identified 
by an immunospot reader and image analyzer (Thermo Scientific). For 
intracellular cytokine staining (ICS), splenocytes were stimulated with 
an HIV-1 p24 peptide pool (2 μg/ml for each peptide) in the presence 
of costimulatory anti-CD28 antibody (2 μg/ml, eBioscience) for 20 to 
24 hours at 37°C. Brefeldin A (10 μg/ml; Sigma-Aldrich) was added for 
the last 5 hours to accumulate intracellular cytokines. Cells were washed 
and incubated with 2.4G2 mAb for 15 minutes at 4°C to block Fcγ. After 
cess in amplifying CD8+ T cell immune responses (14–17). To 
further determine the underlying mechanism of an sPD1-based 
vaccine, we directly compared it with the conventional anti-
DEC205–based DC-targeting approach (16, 28). By performing 
sPD1-p24fc/EP and anti–DEC205-p41/EP vaccination in mice, 
we found that although both strategies elicited statistically insig-
nificant levels of CD4+ T cell and antibody responses (Figure 7, B 
and D), sPD1-p24fc/EP induced significantly greater numbers of 
antigen-specific CD8+ T cells by ELISPOT (Figure 7A; P < 0.05), 
tetramer staining (Figure 7C; P < 0.05), and intracellular assays 
(Figure 7E; P < 0.05). We then investigated the role of costimula-
tory molecules, Th1-polarizing cytokine production, and antigen 
presentation/cross-presentation pathways in DCs, all of which 
may enhance antigen-specific CD8+ T cell immunity as previously 
described (61). When we examined the DCs in draining lymph 
nodes after vaccination, we found that sPD1-p24fc/EP and anti–
DEC205-p41/EP achieved comparable levels of antigen uptake 
(Supplemental Figure 5A), costimulatory molecule expression 
(Figure 8A), and a similar frequency of IFN-γ–producing DCs 
(Figure 8D). In contrast, a noticeably higher frequency of IL-12–
producing DCs was only detected with sPD1-p24fc/EP vaccina-
tion, suggesting that an IL-12–mediated mechanism underlies 
the increase in CD8+ T cell response (47). This finding is in line 
with the notion that DC-produced IL-12 is the primary cytokine 
enhancing the frequency of IFN-γ–producing antigen–specific 
CD8+ T cells (Figure 5, A–D) (45). It is also in line with our data 
showing that p24 antigen delivered by sPD1-p24 is routed to 
Rab14 endosomes for MHC class I presentation to CD8+ T cells 
(46), as well as to late Lamp1 endosomes for MHC class II pre-
sentation to CD4+ T cells, which is used by both DC-targeting 
strategies to induce similar CD4+ T cell and antibody responses 
(Figure 7B, Figure 8, E and F) (49, 51, 52). These findings are 
novel, we believe, and suggest that antigen targeting to DCs via 
different surface receptors may activate distinct intercellular 
pathways for IL-12 production and antigen cross-presentation. 
Future studies, however, should be conducted to reveal the endo-
cytic function following sPD1 binding to PD-L1/L2, the induc-
tion of IL-12 expression, and to determine whether a difference 
in antigen uptake and processing occurs in other more defined 
DC subsets (46, 62).
Methods
Construction of sPD1-based vaccine and controls. We constructed 3 DNA vac-
cines: sPD1-p24fc, sΔPD1-p24fc, and p24fc on a background of pVAX1 
(Figure 1A). The coding sequence for the extracellular domain of murine 
PD1 (sPD1) was obtained by nested PCR from mouse cDNA (mPD1F-B: 
5′-CGCGGATCCGCG ATGTGGGTCCGGCAGGTA-3′ ; mPD1B-E: 
5′-CCGGAATTCCGGTTGAAACCG GCCTTCTGG-3′), and the HIV-1 
p24 fragment was amplified from a primary isolate HIV-102HNsq4 of a 
Chinese patient without codon optimization. To increase the flexibility 
of the fusion protein, a linker GGGGSGGGG (nt sequence: GGTGGT-
GGTTCAGGAGGAGGA) was applied between the sPD1 and HIV1 p24 
gene. A mutant form of sPD1 (sΔPD1) was also cloned following the same 
strategy as used with wild-type PD1. sΔPD1 does not react with PD1 lig-
ands due to an in-frame deletion of 2 essential amino acids (position 89-90) 
in the IgV domain. Plasmid expressing HIV-1 p24 alone served as a control. 
All plasmids contained a rabbit Fc tag to facilitate protein purification and 
characterization. Plasmids without a rabbit Fc tag, or sPD1 without p24, 
were generated by restriction enzyme digestion and re-ligation, and were 
verified by sequencing. DNA transfection into (HEK-)293T cells was per-
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Godwin Nchinda. Protein expression of these plasmids from transfected 
293T cells was detected at similar levels by Western blot analysis (data not 
shown). The DNAs psc-DEC-p41, psc-Cont-p41, sPD1-p24fc, and p24fc 
were used to immunized mice via i.m./EP at a dose of 100 μg. PBS served 
as a control. The immunization procedure and immune response analysis 
were the same as described above.
Effects of sPD1-based vaccine on DCs. Splenocytes isolated from naive 
BALB/c mice were enriched using a Dynabeads Mouse CD11c+ DC 
Enrichment Kit (Invitrogen). The expression plasmids of encoded 
anti-mouse DEC205 fused to HIV GAG p24 was provided by Christine 
Trumpfheller. CD11c+ splenic DCs (1 × 106) were treated with purified 
sPD1-p24fc or anti–DEC205-p24, p24fc proteins for 20 minutes at room 
temperature. Goat anti-rabbit IgG (HL)-FITC (Invitrogen) was used to 
capture the positive signals. FITC-rat anti-mouse PD-L1 or PD-L2 anti-
bodies (eBioscience) were used to confirm the expression of PD1 ligands 
on the surface of DCs. Goat anti-rabbit IgG (HL)-FITC stained with DCs 
cultured in medium only served as a negative control. FITC-rat anti-
mouse PD-L1 or PD-L2 antibodies (eBioscience) were used to confirm 
the expression of PD1 ligands on the surface of DCs. Goat anti-rabbit 
IgG (HL)-FITC stained with DCs cultured in medium only served as a 
negative control. For antigen uptake analysis, 1 × 106 splenic CD11c+ 
DCs were cultured with 2 μg of purified sPD1-p24fc or sΔPD1-p24fc, 
anti-DEC205-p24 antibody, and p24fc proteins at 4°C for 1 hour. PBS 
served as a negative control. Cells were collected and permeabilized in 
100 μl of Fixation/Permeabilization solution (BD Biosciences) for 20 
minutes at 4°C, washed with Perm/Wash buffer (BD Biosciences), and 
then stained intracellularly with goat anti-rabbit IgG (HL)-FITC. Data 
were acquired on an FACSCalibur instrument (BD Biosciences) and ana-
lyzed using CellQuest software (BD Biosciences).
For in vivo antigen targeting analysis, DNA vaccines of sPD1-p24fc 
or sΔPD1-p24fc, anti–DEC205-p41, and p24fc were administered i.m. 
with EP to BALB/c mice at a 100-μg dose. PBS served as a negative con-
trol. Mice were sacrificed at 4, 8, 16, 24, and 72 hours after injection. 
Draining lymph nodes were extracted and single cells were isolated. 
Cells were stained with surface antibodies: anti-CD11c-APC/Cy7; anti-
MHC II-PE; anti–CD80-APC; anti–CD86-PerCP/Cy5.5; anti–CD40-PE/
Cy5; anti–PD-1-PE/Cy7; anti–PD-L1-PE; anti–PD-L2-FITC; and anti–
CD3-Pacific Blue (eBioscience). These stained cells were permeabilized 
in 100 μl of Fixation/Permeabilization solution (BD Biosciences) for 
20 minutes at 4°C, washed with Perm/Wash buffer (BD Biosciences), 
and then stained intracellularly with FITC-conjugated mouse anti–
HIV-1 p24 antibody (KC57 FITC; Beckman Coulter), FITC-conjugated 
anti-mouse IL-12 (eBioscience), and PE-conjugated anti-mouse IFN-γ 
(eBioscience). Flow cytometric data were acquired and analyzed on a 
FACSAria III flow cytometer (BD Biosciences).
To confirm in vivo antigen presentation, we constructed sPD1-OVAfc 
and sPD1-OVAfc by replacing HIV-1 p24 antigen with ovalbumin (OVA). 
C57BL/6 mice were immunized with sPD1-OVAfc, and controls with 
sΔPD1-OVAfc and sPD1-p24fc delivered by i.m./EP at a dose of 100 μg 
DNA. The next day, 2 × 106 CFSE-labeled OT-I or OT-II T cells were adop-
tively transferred into B6 mice by tail vein injection. Five days after immu-
nization, draining lymph nodes were harvested and the extent of CFSE 
dilution determined among OT-I or OT-II T cells by flow cytometry.
Immunofluorescence. Splenic DCs were enriched from total splenocytes 
using a Dynabeads Mouse CD11c+ DC Enrichment Kit (Invitrogen), 
seeded on a 96-well black plate (ibidi) overnight, and treated with p24, 
sPD1-p24, or anti–DEC205-p41 proteins at 37°C for 15 minutes, 30 
minutes, 1 hour, and 2 hours. After treatment, cells were briefly cen-
trifuged and fixed with 2% paraformaldehyde for 40 minutes at room 
temperature as previously described (49). Next, permeabilization using 
surface staining with anti-mouse CD3-APC/Cy7, CD4-PE/Cy5, and CD8-
PerCP/Cy5.5 antibodies (eBioscience), cells were permeabilized in 100 μl 
of Fixation/Permeabilization solution (BD Biosciences) for 20 minutes at 
4°C, washed with Perm/Wash buffer (BD Biosciences), and then stained 
intracellularly with anti–IFN-γ-PE, anti–IL-2-PE-Cy7, and anti–TNF-α-
FITC (eBioscience). Tetramer-positive CD8+ T cell populations were eval-
uated using PE-conjugated MHC class I tetramer H2d-Kd-AMQMLKDTI 
(Beckman Coulter).
T cell proliferation assay. Splenocytes isolated from BALB/c mice 30 weeks 
after the final immunization were labeled with CFSE (107 cells/ml in PBS, 
1 μM, 10 minutes at 37°C water bath; Invitrogen). Labeled cells were 
stimulated with bone marrow–derived DCs (BM-DCs) at a ratio of 10:1 in 
the presence of HIV-1 GAG p24 peptide pools (2 μg/ml), and anti-CD28 
(2 μg/ml) or anti-CD3 (0.1 μg/ml) antibodies were used as positive con-
trols. BM-DCs from BALB/c mice were obtained from bone marrow 
extracts and cultured for 7 days in the presence of murine GM-CSF (10 
U/ml; Sigma-Aldrich) and IL-4 (10 U/ml; Sigma-Aldrich), then enriched 
using a Dynabeads Mouse CD11c+ DC Enrichment Kit (Invitrogen). Five 
days after coculture, cells were collected and stained with CD3-APC/Cy7, 
CD4-PE/Cy5, CD8-PerCP/Cy5.5 antibodies. Flow cytometric data were 
acquired and analyzed on a FACSAria III flow cytometer (BD Biosciences).
Cytotoxicity assay. AB1 cells were purchased from the European Collection 
of Cell Cultures. Cells were cultured in RPMI1640 supplemented with 10% 
FBS, L-glutamine, and antibiotics. The cell line was maintained in vitro at 
37°C in a humidified atmosphere containing 5% CO2. Based on the origi-
nal pBABE-puro vector, we generated the transfer vector pBABE-HIVgag/
Luc for the construction of the AB1-HIVgag-luc cell line, which encodes 
a fusion form of the full-length HIV gag gene with firefly luciferase. Since 
the original LTR promoter on the vectors is considered a weak promoter, 
we inserted a CMV promoter obtained from the pVAX1 vector and inserted 
it upstream of the fusion gene to drive a higher level of transcription and 
protein expression. Retrovirus was packaged by cotransfection of the pCL 
packaging vector and transfer plasmid (pBABE-HIVgag/Luc) into 293T 
cells. Retrovirus-containing supernatants were collected and used to infect 
AB1 cells followed by puromycin selection. Single clones were selected by 
limiting dilution of the drug-resistant cells in 96-well plates. Following 
single clone cultures, HIV GAG expression was confirmed and validated 
by flow cytometry. Then we used the LIVE/DEAD Viability/Cytotoxicity 
Kit (Invitrogen) to assess the cytotoxic effects of purified CD4+ and CD8+ 
T cells isolated from vaccinated mice (Dynabeads CD4 Negative Isola-
tion Kit and Dynabeads CD8 Negative Isolation Kit; Invitrogen). Purified 
T cells and target AB1-HIV-1-GAG cells were cocultured for 2 hours at 
37°C then analyzed for the percentage of dead target cells in total AB1-
HIV-1-GAG cell populations on an FACSCalibur instrument (BD Biosci-
ences) using CellQuest software (BD Biosciences).
Vaccinia viral challenge. Immunized mice were challenged intranasally by 
4 × 107 PFUs of a modified vaccinia Tian Tan strain or 2 × 106 PFUs of 
the vaccinia Western Reserve (WR) strain, which expresses HIV gag and 
pol genes. The pathogenic vaccinia WR strain was purchased from ATCC 
(ATCC VR-1354) and propagated in Vero cells. The virus was modified to 
express HIV-1 gag and pol genes in place of the hemagglutinin gene. Animal 
body weight was monitored daily. Groups of animals were also sacrificed 
3 days or 8 days after challenge by VTTgagpol or WRgagpol, respectively, 
to measure viral titers in their lungs. Lung homogenates were prepared 
by physical disruption and by passing cells through cell strainers, and 
virus titers in the lungs were determined by a plaque-forming assay on 
monolayer Vero cells and monitored for cytopathic effect over time.
Comparison of anti-DEC205- and sPD1-based vaccines. The single chain of 
anti-mouse DEC205 fused with HIV-1 p41 psc-DEC-p41 (antigen p41 con-
sists of p24 and p17) and control plasmid psc-Cont-p41 were provided by 
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blocking buffer PBS with 5% FBS, 3% BSA, and 0.5% Triton X-100 was 
performed for 20 minutes at 4°C before incubation with primary anti-
bodies against Rab5, Rab7, Rab9, Rab14, Lamp1 (Sigma-Aldrich), and 
anti–HIV-1 GAG monoclonal antibody for 12 hours at 4°C in a stain-
ing buffer of PBS with 3% BSA and 0.1% Triton X-100. Secondary anti-
bodies Alexa Fluor 488 donkey anti-mouse and Alexa Fluor 555 donkey 
anti-rabbit IgG (Invitrogen) were used for fluorescence staining at room 
temperature for 1 hour, followed by mounting using SlowFade Gold 
antifade reagent with DAPI. Signals were acquired using a Carl Zeiss 
LSM 700 microscope and images were analyzed using ZEN software. 
ImageJ software (http://imagej.nih.gov/ij/, 1997–2012) (63) with a 
JACoP plug-in was used to calculate various colocalization coefficients: 
Pearson’s correlation, overlap coefficient, and Mander’s coefficient, as 
reported in Supplemental Table 1.
Statistics. All statistical analyses were performed using the 2-tailed Stu-
dent’s t test. P values less than 0.05 were considered statistically significant. 
Data are presented as the mean values ± SEM of at least 3 independent 
experiments unless otherwise indicated.
Study approval. Handling, experimental procedures including injections, 
blood collection, virus challenge, and sacrificing were approved and per-
formed according to the University of Hong Kong Committee on the Use 
of Live Animals in Teaching and Research (CULATR 1881-09 and 1922-09).
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